Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Cobiprostone for the Prevention of Severe Oral Mucositis in Subjects With Head and Neck Cancer (HNC)

Next Previous
Trial Profile

A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Cobiprostone for the Prevention of Severe Oral Mucositis in Subjects With Head and Neck Cancer (HNC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobiprostone (Primary)
  • Indications Stomatitis
  • Focus Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals

    • Most Recent Events

    • 11 Jul 2016 According to a Sucampo Pharmaceuticals media release, the company announced the decision to discontinue the development of cobiprostone based on the results of a prespecified futility analysis of this trial. The futility analysis indicated that the clinical benefit of cobiprostone was insufficient to support continuation of the study.
    • 11 Jul 2016 Status changed from recruiting to discontinued, according to a Sucampo media release.
    • 20 May 2016 Treatment arms changed from 3 to 2 with removal of Cobiprostone 15 mcg dose.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top